León-González M, León-Peña AA, Vallejo-VIllalobos MF, Núñez-Cortés AK, Ruiz-Argüelles A, Ruiz-Argüelles GJ

Idioma: Ingles.
Referencias bibliográficas: 11
Paginas: 181-183
Archivo PDF: 52.69 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Abboud C, Berman E, Cohen A, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood. 2013;121:4439-42.

2. Danylesko I, Sareli R, Bloom-Varda N, et al. Biosimilar filgrastim (Tevagrastim, XMO2) for allogeneic hematopoietic stem cell mobilization and transplantation in patients with acute myelogenous leukemia/myelodysplastic syndromes. Biol Blood Marrow Transplant. 2016;22:277-83.

3. Nahon S, Rastkhah M, Ben Abdelghani M, Soumoudronga RF, Gasnereaus I, Labourey JL. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: A French prospective multicentric study. Support Care Cancer. 2016;24:1991-8.

4. Thompson CA. Biosimilar filgrastim approved, but with “placeholder” generic name. Am J Health Syst Pharm. 2015;72:592-4.

5. Ruiz-Argüelles GJ, Leon-Peña AA, Leon-Gonzalez M, et al. Outpatient hematopoietic grafting in patients with multiple sclerosis employing autologous non-cryopreserved peripheral blood stem cells: A feasibility study. Br J Haematol 2016;173 (Suppl. 1):17.

6. Sivgin S, Karakus E, Kaynar L, et al. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: A single center experience from Turkey. Transfus Apher Sci. 2013;48:315-20.

7. Martino M, Recchia AG, Moscato T, et al. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Cytotherapy. 2015;17:1485-93.

8. Cesaro S, Tridello G, Prete A, et al. Biosimilar granulocyte-colonystimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients. Transfusion. 2015;55:246-52.

9. Watanabe H, Watanabe T, Suzuya H, et al. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Bone Marrow Transplant. 2006;37:661-8.

10. Yafour N, Brahimi M, Osmani S, Arabi A, Bouhass R, Bekadja MA. Biosimilar G-CSF (filgrastim) is effective for peripheral blood stem cell mobilization and non-cryopreserved autologous transplantation. Transfus Clin Biol. 2013;20:502-4.

11. Manko J, Walter-Croneck A, Jawniak D, et al. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacol Rep. 2014;66:239-42.